Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.91 (market cap $39.89B), while GraniteShares 2x Long NVDA Daily ETF trades at $31.59. The key difference: GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NVDL | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $43.02 |
52-Week Low | $278.09 | $21.76 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $33.03, up 8.08% with a bullish technical signal. Recent stock splits (1:3 on June 25-26, 2026) reflect volatility management. The ETF has shown strong YTD performance (+12.66% as of June 8, 2026) but remains highly sensitive to NVIDIA's daily moves, evidenced by a 12% single-day drop on June 5, 2026. Technical indicators show bullish moving averages but neutral oscillators, with key resistance at $33.
Outlook: High-growth potential tied to NVIDIA's AI dominance, but leveraged structure amplifies risks. Daily resets can erode value during volatility, as seen in early 2025's 67% decline. Investors must weigh AI-driven upside against compounded losses in downtrends. Key risks include NVIDIA-specific volatility and broader semiconductor cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
